Safety

News

Adverse events have led Keros to abandon a phase 2 trial of pulmonary arterial hypertension drug cibotacept, a would-be rival to MSD's Winrevair.

News

An unexpected side effect has led Keros to halt dosing in two arms of its phase 2 trial of pulmonary arterial hypertension drug cibotercept.

News

Liver safety signal leads BioAge to discontinue its phase 2 trial of obesity candidate azelaprag, hitting the Nasdaq debutante's share price.

News

The FDA is scrutinising reports of haematological cancers in patients treated with bluebird bio's Skysona gene therapy for neurological disease CALD

News

The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died

News

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares.